2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CLINICAL CANCER RESEARCH CLIN CANCER RES LetPub评分 9.3
51人评分
我要评分
声誉 9.9 影响力 8.7 速度 9.6 | |||||||||||||||||||||
| 期刊ISSN | 1078-0432 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1557-3265 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 2.50%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 292 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease. | |||||||||||||||||||||
| 期刊官方网站 | http://clincancerres.aacrjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://ccr.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CLINICAL CANCER RESEARCH的语言要求，还能让CLINICAL CANCER RESEARCH编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CLINICAL CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||||||
| 出版年份 | 1995 | |||||||||||||||||||||
| 年文章数 | 642注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 2.32% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 94.39% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1078-0432%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2.1月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约30% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CLINICAL CANCER RESEARCH顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma. Author: Zhang JY#1, Zhang PP#1, Zhou WP#1, Yu JY2, Yao ZH1, Chu JF1, Yao SN1, Wang C2, Lone W2, Xia QX3, Ma J3, Yang SJ1, Liu KD4,5, Dong ZG4, Guo YJ3, Smith LM6, McKeithan TW7, Chan WC8, Iqbal J9, Liu YY10. Journal: Clin Cancer Res. 2019 Mar 1. doi: 10.1158/1078-0432.CCR-18-2146. [Epub ahead of print] PubMed DOI |
| 2. | Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. Author: Jia X#1,2,3, Li C#2,3, Li L3, Liu X4, Zhou L3, Zhang W1,2, Ni S3, Lu Y3, Chen L1,2, Jeong LS5, Yu J5, Zhang Y6,7, Zhang J6,7, He S6,7, Hu X1,2, Sun H1,2, Yu K1,2, Liu G1,2, Zhao H8, Zhang Y8, Jia L9, Shao ZM10,2. Journal: Clin Cancer Res. 2019 Mar 4. doi: 10.1158/1078-0432.CCR-18-2434. [Epub ahead of print] PubMed DOI |
| 3. | Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Author: Xu J1, Li J2, Bai C3, Xu N4, Zhou Z5, Li Z6, Zhou C7, Jia R8, Lu M2, Cheng Y3, Mao C4, Wang W5, Cheng K6, Su C7, Hua Y9, Qi C9, Li J9, Wang W9,10, Li K9, Sun Q9, Ren Y9, Su W9. Journal: Clin Cancer Res. 2019 Mar 4. doi: 10.1158/1078-0432.CCR-18-2994. [Epub ahead of print] PubMed DOI |
| 4. | HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma. Author: Li H#1, Li J#1, Chen L#1, Qi S#1,2,3, Yu S4, Weng Z1, Hu Z5, Zhou Q1, Xin Z1, Shi L1, Ma L1, Huang A6, Lu Y7,2,3. Journal: Clin Cancer Res. 2019 Mar 12. doi: 10.1158/1078-0432.CCR-18-3791. [Epub ahead of print] PubMed DOI |
| 5. | PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Author: Chung EY1, Mai Y1, Shah UA2, Wei Y1,3, Ishida E1, Kataoka K4, Ren X5, Pradhan K6, Bartholdy B1, Wei X1,3, Zou Y2, Zhang J5, Ogawa S7, Steidl U1, Zang X5, Verma A2,5, Janakiram M2, Ye BH8. Journal: Clin Cancer Res. 2019 Mar 12. doi: 10.1158/1078-0432.CCR-18-3033. [Epub ahead of print] PubMed DOI |
| 6. | Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs. Author: Kiseleva AA1,2, Korobeynikov VA1,3, Nikonova AS1, Zhang P1,4, Makhov P5, Deneka AY1,2, Einarson MB1, Serebriiskii IG1,2, Liu H4, Peterson JR5, Golemis EA6. Journal: Clin Cancer Res. 2019 Mar 13. doi: 10.1158/1078-0432.CCR-18-3535. [Epub ahead of print] PubMed DOI |
| 7. | Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing. Author: Tian T#1, Lv X#2,3, Pan G#1,4, Lu Y#1, Chen W#1,4, He W5, Lei X1, Zhang H1, Liu M1, Sun S6, Ou Z1, Lin X1, Cai L7, He L7, Tu Z7, Wang X7, Tannous BA8, Ferrone S7, Li J9,4, Fan S9,4,7. Journal: Clin Cancer Res. 2019 Mar 18. doi: 10.1158/1078-0432.CCR-18-2739. [Epub ahead of print] PubMed DOI |
| 8. | The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy. Author: Cheng J#1, He S#1, Wang M2, Zhou L3, Zhang Z1, Feng X1, Yu Y1, Ma J4, Dai C5, Zhang S5, Sun L5, Gong Y1, Wang Y1, Zhao M1, Luo Y1, Liu X6, Tian L5, Li C7, Huang Q8. Journal: Clin Cancer Res. 2019 Mar 19. doi: 10.1158/1078-0432.CCR-18-3001. [Epub ahead of print] PubMed DOI |
| 9. | Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. Author: Heigener DF1,2,3, Kerr KM4, Laing GM4, Mok TSK5, Moiseyenko FV6,7, Reck M8,9,3. Journal: Clin Cancer Res. 2019 Mar 25. doi: 10.1158/1078-0432.CCR-18-1894. [Epub ahead of print] PubMed DOI |
| 10. | CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC. Author: Liu Y1,2, Liu L1, Zhou Y1, Zhou P1, Yan Q1, Chen X3, Ding S1, Zhu F4,2,5. Journal: Clin Cancer Res. 2019 Mar 27. doi: 10.1158/1078-0432.CCR-18-3510. [Epub ahead of print] PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共6条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
